Bone Marrow Transplant
Aug 23, 2022
EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib
EU Regulator Starts its Review of Cidara Therapeutics’ Candidiasis Therapy Rezafungin The EU regulator has begun its review of Cidara Therapeutics’ once-weekly antifungal rezafungin, with a decision expected next year as a new option for serious, invasive candida infections. The application is based on the ReSTO...
Read More...
Oct 23, 2017
Metachromatic Leukodystrophy (MLD): A Rare Indication with great unmet medical need
Metachromatic Leukodystrophy (MLD) is a rare lysosomal storage disease which is genetic, degenerative, neurometabolic in nature. It is generally inherited from carrier parents and at present doesn’t have any cure. Patients suffering from MLD are deficient in the arylsulfatase-A enzyme, which is responsible for break...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
